AVITA Medical Hits 52-Week Low at $3.37 Amidst Significant Decline

AVITA Medical, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 3.37 on November 6, 2025. This significant decline marks a stark contrast to its 52-week high of USD 14.16, reflecting a challenging year for the company with a performance drop of 62.47%.
The company's market capitalization stands at USD 112 million, indicating its microcap status. AVITA Medical has not reported a price-to-earnings ratio due to its loss-making position, and it offers no dividend yield. Financial metrics reveal a negative book value, which contributes to concerns regarding its long-term fundamental strength. The company's operating profit has decreased at an annual rate of 27.43% over the past five years, and its ability to manage debt is under scrutiny, highlighted by a poor EBIT to interest ratio of -30.23.

Despite a reported increase in profits of 53.9% over the past year, the stock has generated a return of -68.67%, underperforming the S&P 500 across various time frames. This performance underscores the challenges AVITA Medical faces in the current market landscape.